To date, various EGFR inhibitors have been developed as chemotherapeutic agents against NSCLC, and afatinib, gefitinib and erlotinib are the preferred first-line treatments in patients with advanced NSCLC 6. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.